logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
C

Changsong Qi

Peking University Cancer Hospital and Institute
H指数:28
被引数:3,325

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Extracellular vesicle proteins monitor and interfere with CLDN18.2-targeted CAR-T cell and antibody therapies against gastrointestinal cancers

外泌体蛋白监测并干扰CLDN18.2靶向CAR-T细胞和抗体疗法对胃肠道肿瘤的治疗

Nature Communications
IF15.7
2026-09-030
OA
Changsong Qi; Mingyang Ma; Kaijie Liang; Chang Liu; Jiarui Li; Yakun Wang; Dan Liu; Miao Zhang; Xiaoyi Chong; Fangli Jiang; Shengde Liu; Zizhen Zhang; Congcong Ji; Yuezong Bai; Meng Fan; Chuanhui Han; Xiaotian Zhang; Jifang Gong; Jian Li; Lin Shen; Cheng Zhang
Efficacy and safety of infigratinib in patients with refractory advanced gastric or gastroesophageal junction adenocarcinoma harboring FGFR2 gene amplification: a single-arm, multicenter phase 2 trial

携带FGFR2基因扩增的难治性晚期胃或胃食管结合部腺癌患者中Infigratinib的疗效与安全性：一项单臂、多中心II期试验

British Journal of Cancer
IF6.8
2026-06-230
PRE
Jiajia Yuan; Jifang Gong; Zhi Peng; Tian Shu Liu; HuiTing Xu; Jianwei Yang; Jia Wei; Haiping Jiang; Yanhong Deng; Yusheng Wang; Changsong Qi; Cheng Lyu; Qiao Sun; Lei Mu; Lin Song; Xiaotian Zhang; Lin Shen
A bispecific antibody–drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: a phase 1b trial

一种靶向EGFR和HER3的双特异性抗体药物偶联物在转移性食管鳞状细胞癌中的研究：一项1b期临床试验。Nat. Med

Nature Medicine
IF50
2025-07-100
OAAI
Chang Liu; Dan Liu; Yinghua Ji; Meili Sun; Shegan Gao; Xuelei Ma; Diansheng Zhong; Ji Zhu; Yanshuo Cao; Changsong Qi; Miao Zhang; Panpan Zhang; Ran Xue; Zhi Peng; Jun Zhou; Sai Ge; Ming Lu; Jiajia Yuan; Yakun Wang; Zhenghang Wang; Jian Li; Xiaotian Zhang; Yi Zhu; Hai Zhu; Sa Xiao; Jifang Gong; Lin Shen; Zhihao Lu
Efficacy and safety of KN026, a bispecific anti-HER2 antibody, in combination with KN046, an anti-CTLA4/PD-L1 antibody, in patients with advanced HER2-positive nonbreast cancer: a combined analysis of a phase Ib and a phase II study

KN026（一种双特异性抗HER2抗体）与KN046（一种抗CTLA4/PD-L1抗体）联合治疗晚期HER2阳性非乳腺癌患者的有效性与安全性：一项Ib期和II期研究的合并分析

SIGNAL TRANSDUCTION AND TARGETED THERAPY
IF52.7
2025-03-190
OA
Liu, Dan; Gong, Jifang; Li, Jian; Qi, Changsong; Niu, Zuoxing; Liu, Bo; Peng, Zhi; Luo, Suxia; Wang, Xicheng; Wang, Yakun; Zhao, Rusen; Chen, Lilin; Deng, Ting; Li, Zhen; Chen, Lei; Fang, Meimei; Yang, Hongwei; Lu, Linzhi; Zhang, Yanming; Kang, Fengling; Xu, Ting; Zhang, Xiaotian

研究方向

暂未获取到该数据
J
Jifang Gong
H 指数:36论文数:226被引数:5,429
L
Lin Shen
H 指数:62论文数:827被引数:2.6万
Z
Zhi Peng
H 指数:34论文数:158被引数:4,224
L
Lin Shen
H 指数:57论文数:545被引数:1.8万
张笑天 封面图
张笑天
H 指数:38论文数:186被引数:4,416
李健 封面图
李健
H 指数:34论文数:276被引数:4,747
J
Jiajia Yuan
H 指数:33论文数:141被引数:4,377
Z
Zhenghang Wang
H 指数:26论文数:85被引数:2,627
X
Xicheng Wang
H 指数:36论文数:331被引数:6,452
Y
Yakun Wang
H 指数:14论文数:51被引数:1,694